首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   676篇
  免费   43篇
耳鼻咽喉   13篇
儿科学   149篇
妇产科学   11篇
基础医学   78篇
口腔科学   1篇
临床医学   40篇
内科学   163篇
皮肤病学   8篇
神经病学   29篇
特种医学   6篇
外科学   75篇
综合类   22篇
预防医学   55篇
眼科学   24篇
药学   24篇
中国医学   1篇
肿瘤学   20篇
  2023年   3篇
  2022年   4篇
  2021年   13篇
  2020年   4篇
  2019年   9篇
  2018年   14篇
  2017年   10篇
  2016年   19篇
  2015年   10篇
  2014年   17篇
  2013年   36篇
  2012年   51篇
  2011年   30篇
  2010年   18篇
  2009年   15篇
  2008年   45篇
  2007年   50篇
  2006年   41篇
  2005年   41篇
  2004年   27篇
  2003年   36篇
  2002年   15篇
  2001年   20篇
  2000年   9篇
  1999年   22篇
  1998年   12篇
  1997年   9篇
  1995年   5篇
  1994年   5篇
  1993年   5篇
  1992年   13篇
  1991年   7篇
  1990年   5篇
  1989年   4篇
  1988年   6篇
  1987年   8篇
  1985年   8篇
  1984年   3篇
  1983年   8篇
  1982年   10篇
  1981年   5篇
  1979年   3篇
  1975年   6篇
  1974年   5篇
  1973年   4篇
  1972年   7篇
  1971年   5篇
  1970年   3篇
  1969年   2篇
  1968年   3篇
排序方式: 共有719条查询结果,搜索用时 15 毫秒
91.
92.
93.
94.
Summary A ten-year-old boy presenting with lymphadenopathy and hepatomegaly was found to have hemosiderosis on a lymphnode biopsy. Investigations revealed that he had ingested excessive amounts of iron leading to hemosiderosis. Other causative factors were excluded. After omission of further iron ingestion, the child improved. From the Department of Pediatrics, All India Institute of Medical Sciences, New Delhi 1–6.  相似文献   
95.
Angiotensin (Ang) II type 2 (AT(2)) receptors are believed to counteract Ang II type 1 (AT(1)) receptor-mediated effects. Here, we investigated AT(2) receptor-mediated effects on coronary and cardiac contractility in C57BL/6 mice. Hearts were perfused according to Langendorff. Baseline coronary flow (CF) and left ventricular systolic pressure (LVSP) were 2.7 +/- 0.1 ml min(-1) and 111 +/- 3 mmHg (n = 50), respectively. Ang II (n = 14) concentration dependently decreased CF and LVSP, by maximally 41 +/- 4 and 25 +/- 3%, respectively (pEC(50)s 7.41 +/- 0.12 and 7.65 +/- 0.12). The AT(1) receptor antagonist irbesartan (n = 4) abolished all Ang II-induced changes, whereas the AT(2) receptor antagonist PD123319 (n = 6) enhanced (P < 0.05) the effect of Ang II on CF (to 59 +/- 1%) and LVSP (to 44 +/- 2%), without altering its potency. A similar enhancement was observed in the presence of nitric oxide (NO) synthase inhibitor N(omega)-nitro-L-arginine methyl ester HCl (L-NAME; n = 4). On top of L-NAME, PD123319 no longer affected the response to Ang II (n = 4). The AT(2) receptor agonist CGP42112A (n = 4) did not affect CF or LVSP, nor did CGP42112A (n = 4) alter the constrictor response to the alpha(1)-adrenoceptor agonist phenylephrine. Furthermore, Ang II exerted no effects in hearts of AT(1A)(-/-) mice (n = 5), whereas its effects in hearts of AT(1A)(+/+) wild-type control mice (n = 7) were indistinguishable from those in hearts of C57BL/6 mice. In conclusion, Ang II exerts opposite effects on coronary and cardiac contractility in the mouse heart via activation of AT(1A) and AT(2) receptors. AT(2) receptor-mediated effects depend on NO and occur only in conjunction with AT(1A) receptor activation.  相似文献   
96.
97.
98.
99.
Polyclonal antibodies have a century-old history of being effective against some viruses and, recently, monoclonal antibodies (mAbs) have also shown some clinical success. Human mAbs to the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein have been developed by several research groups at an amazing pace. These antibodies potently neutralize infectious virus in tissue cultures and animal models, and, alone or in combination with vaccines and other drugs, may have potential for the prevention and treatment of SARS.  相似文献   
100.

Background

The low-carbohydrate, ketogenic diet (LCKD) may be effective for improving glycemia and reducing medications in patients with type 2 diabetes.

Methods

From an outpatient clinic, we recruited 28 overweight participants with type 2 diabetes for a 16-week single-arm pilot diet intervention trial. We provided LCKD counseling, with an initial goal of <20 g carbohydrate/day, while reducing diabetes medication dosages at diet initiation. Participants returned every other week for measurements, counseling, and further medication adjustment. The primary outcome was hemoglobin A1c.

Results

Twenty-one of the 28 participants who were enrolled completed the study. Twenty participants were men; 13 were White, 8 were African-American. The mean [± SD] age was 56.0 ± 7.9 years and BMI was 42.2 ± 5.8 kg/m2. Hemoglobin A1c decreased by 16% from 7.5 ± 1.4% to 6.3 ± 1.0% (p < 0.001) from baseline to week 16. Diabetes medications were discontinued in 7 participants, reduced in 10 participants, and unchanged in 4 participants. The mean body weight decreased by 6.6% from 131.4 ± 18.3 kg to 122.7 ± 18.9 kg (p < 0.001). In linear regression analyses, weight change at 16 weeks did not predict change in hemoglobin A1c. Fasting serum triglyceride decreased 42% from 2.69 ± 2.87 mmol/L to 1.57 ± 1.38 mmol/L (p = 0.001) while other serum lipid measurements did not change significantly.

Conclusion

The LCKD improved glycemic control in patients with type 2 diabetes such that diabetes medications were discontinued or reduced in most participants. Because the LCKD can be very effective at lowering blood glucose, patients on diabetes medication who use this diet should be under close medical supervision or capable of adjusting their medication.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号